Xeris Biopharma Holdings IncNASDAQ:XERS
- LAST PRICE2.8500
- TODAY'S CHANGE (%)0.0200 (0.7067%)
- Bid / Lots2.8500/ 53
- Ask / Lots2.8600/ 34
- Open / Previous Close2.8600 / 2.8300
- Day Range
- 52 Week Range
- Volume357,952
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XERS |
|---|---|---|
| 09:32 ET | 4773 | 2.86 |
| 09:34 ET | 20035 | 2.845 |
| 09:36 ET | 2608 | 2.8457 |
| 09:38 ET | 30029 | 2.855 |
| 09:39 ET | 27184 | 2.86 |
| 09:41 ET | 50462 | 2.855 |
| 09:43 ET | 600 | 2.86 |
| 09:45 ET | 10887 | 2.8495 |
| 09:48 ET | 1857 | 2.8521 |
| 09:50 ET | 3263 | 2.8512 |
| 09:52 ET | 7900 | 2.855 |
| 09:54 ET | 7349 | 2.845 |
| 09:56 ET | 1900 | 2.85 |
| 09:57 ET | 2532 | 2.8499 |
| 09:59 ET | 3450 | 2.85 |
| 10:01 ET | 4630 | 2.845 |
| 10:03 ET | 1330 | 2.845 |
| 10:06 ET | 1242 | 2.845 |
| 10:08 ET | 2077 | 2.84 |
| 10:10 ET | 1100 | 2.833919 |
| 10:12 ET | 5200 | 2.83 |
| 10:14 ET | 9010 | 2.8291 |
| 10:15 ET | 2000 | 2.825 |
| 10:17 ET | 19419 | 2.85 |
| 10:19 ET | 1078 | 2.845 |
| 10:21 ET | 300 | 2.85 |
| 10:24 ET | 4666 | 2.855 |
| 10:26 ET | 1933 | 2.8559 |
| 10:28 ET | 1302 | 2.855 |
| 10:30 ET | 1578 | 2.855 |
| 10:32 ET | 978 | 2.855 |
| 10:33 ET | 3000 | 2.84 |
| 10:35 ET | 9779 | 2.855 |
| 10:37 ET | 16869 | 2.85 |
| 10:39 ET | 2400 | 2.865 |
| 10:42 ET | 400 | 2.865 |
| 10:44 ET | 400 | 2.865 |
| 10:46 ET | 1300 | 2.865 |
| 10:48 ET | 1000 | 2.87 |
| 10:50 ET | 3938 | 2.875 |
| 10:51 ET | 2328 | 2.875 |
| 10:53 ET | 500 | 2.875 |
| 10:55 ET | 500 | 2.875 |
| 10:57 ET | 4511 | 2.8657 |
| 11:00 ET | 4565 | 2.865 |
| 11:02 ET | 2556 | 2.86 |
| 11:04 ET | 800 | 2.86 |
| 11:06 ET | 1600 | 2.86 |
| 11:08 ET | 1365 | 2.865 |
| 11:09 ET | 2000 | 2.865 |
| 11:11 ET | 4531 | 2.865 |
| 11:13 ET | 1792 | 2.865 |
| 11:15 ET | 900 | 2.865 |
| 11:18 ET | 1600 | 2.86 |
| 11:20 ET | 4148 | 2.86 |
| 11:22 ET | 1500 | 2.86 |
| 11:24 ET | 3560 | 2.855 |
| 11:26 ET | 2498 | 2.855 |
| 11:27 ET | 1184 | 2.85 |
| 11:29 ET | 3500 | 2.855 |
| 11:31 ET | 600 | 2.85 |
| 11:33 ET | 1800 | 2.85 |
| 11:36 ET | 1200 | 2.85 |
| 11:38 ET | 1290 | 2.855 |
| 11:40 ET | 12292 | 2.85 |
| 11:42 ET | 1957 | 2.85 |
| 11:44 ET | 900 | 2.85 |
| 11:45 ET | 1990 | 2.855 |
| 11:47 ET | 2152 | 2.85 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xeris Biopharma Holdings Inc | 421.7M | -6.8x | --- |
Bavarian Nordic A/S | 2.8B | 25.7x | --- |
SIGA Technologies Inc | 495.3M | 6.1x | -28.78% |
Takeda Pharmaceutical Co Ltd | 46.7B | 45.1x | -8.01% |
Assertio Holdings Inc | 116.3M | -0.3x | --- |
Esperion Therapeutics Inc | 321.8M | -1.9x | --- |
Company Information
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
Contact Information
- Headquarters
- 1375 West Fulton Street, Suite 1300CHICAGO, IL, United States 60607
- Phone
- 302-658-7581
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Marla Persky
- President, Chief Operating Officer
- Kevin McCulloch
- Chief Executive Officer, Director
- John Shannon
- Chief Financial Officer
- Steven Pieper
- Senior Vice President - Global Development and Medical Affairs
- Kenneth Johnson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $421.7M |
|---|---|
Revenue (TTM) | $181.4M |
Shares Outstanding | 149.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.85 |
EPS | $-0.42 |
Book Value | $-0.05 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -23.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
